top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

Updated: Apr 14


13/04/2026










FDA issues Complete Response Letter to Replimune’s RP1 BLA, halting accelerated approval path (Ref)


Replimune received a Complete Response Letter (CRL) from the FDA rejecting its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) + nivolumab in advanced Melanoma


  • Regulatory Concerns:


    • FDA’s review process was inconsistent, with a new team replacing the prior reviewers.


    • Contradictions between earlier FDA guidance (accepting single-arm trial data for accelerated approval) and the CRL


    • Disputes over tumor assessment methodology despite Replimune following FDA’s requested RECIST 1.1 criteria


  • Clinical Data (IGNYTE trial):


    • 34% response rate in patients progressing on prior anti-PD-1 therapy


    • Median response duration: 24.8 months


    • Median progression-free survival: 30.6 months in responders vs. 4.4 months on prior therapy


    • Favorable safety profile


  • Impact:


    • Without accelerated approval, RP1 development is not viable




















FDA Grants Priority Review for Ifinatamab Deruxtecan in ES-SCLC (Ref)


The Biologics License Application (BLA) for ifinatamab deruxtecan has been accepted and granted Priority Review by the U.S. FDA for extensive-stage small cell lung cancer (ES-SCLC) patients whose disease progressed after platinum-based chemotherapy.


  • The FDA is also reviewing it under Real-Time Oncology Review (RTOR) and Project Orbis to accelerate access.


  • Target decision date (PDUFA): October 10, 2026


Clinical Evidence:


  • Based on results from the IDeate-Lung01 phase 2 trial (187 patients globally) and supported by IDeate-PanTumor01 phase 1/2 trial






















Daraxonrasib Demonstrates Unprecedented Survival Benefit in Phase 3 Pancreatic Cancer Trial (Ref)


Revolution Medicines announced positive topline results from its Phase 3 RASolute 302 trial evaluating daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)


  • Daraxonrasib taken orally once daily demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS).


  • Median OS: 13.2 months with daraxonrasib vs. 6.7 months with chemotherapy - HR: 0.40 (p < 0.0001), indicating a strong survival benefit


  • Safety: Generally well tolerated, manageable profile, no new safety signals


Regulatory & Clinical Plans


  • Data will be submitted to the FDA and other global regulators as part of a New Drug Application under a Commissioner’s National Priority Vouche


  • Results will be presented at the 2026 ASCO Annual Meeting






















Jaypirca (pirtobrutinib) combination significantly extended progression-free survival (PFS) in Relapsed/Refractory CLL/SLL (Ref)


Top‑line result from Lilly’s Phase 3 BRUIN CLL‑322 trial shows the study’s primary endpoint was met, with Jaypirca (pirtobrutinib) plus venetoclax‑rituximab significantly extending progression‑free survival versus venetoclax‑rituximab alone in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)


  • Overall survival (OS): Not yet mature, but trending positively for the pirtobrutinib combination


  • Safety profile: Comparable across arms; low discontinuation rates


Detailed results will be presented at a medical congress and submitted to a peer-reviewed journal. Lilly intends to submit these results to regulators later this year for a label expansion























SynOx Therapeutics' Phase 3 TANGENT Study Delivers Positive Results for TGCT Treatment (Ref)


SynOx Therapeutics' Emactuzumab, a short-course CSF-1R inhibitor, has successfully met all primary and secondary endpoints in its pivotal Phase 3 TANGENT trial for Tenosynovial Giant Cell Tumor (TGCT)


  • The trial achieved statistically significant results vs placebo at 6 months, including Objective Response Rate (ORR) by RECIST v1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF and other patient -relevant functional measures


  • SynOx plans to submit a Biologics License Application (BLA) to the FDA in H2 2026, followed by an EU Marketing Authorization Application (MAA)























IDEAYA and Servier report positive Phase 2/3 results for darovasertib + crizotinib in first-line HLA-A*02:01–negative metastatic uveal melanoma (Ref)


The Phase 2/3 registrational trial (OptimUM-02) of darovasertib + crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma met its primary endpoint with a statistically significant improvement in median PFS (6.9 vs 3.1 months; HR: 0.42; p<0.0001)


  • Darovasertib combination reduced risk of disease progression by 58% vs investigator choice of therapy (ICT)


  • Strong ORR: Overall response rate of 37.1% vs. 5.8% for ICT (p<0.0001), including 5 complete responses in the darovasertib arm vs. none in ICT


  • OS Trend: Overall survival data is not yet mature, but an early positive trend was observed for the darovasertib combination vs ICT


  • Safety: Well-tolerated with a manageable safety profile


Upcoming Milestones:


  • NDA Submission: Planned for H2 2026 to the FDA, targeting U.S. accelerated approval


  • Full Data Presentation: Complete OptimUM-02 results to be presented at a major medical conference later in 2026



Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page